New pill for lung disease passes first safety check in healthy people
NCT ID NCT06899815
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new tablet called F230 in 136 healthy adults to see if it is safe and how the body processes it. The drug is designed to treat pulmonary hypertension, a serious lung condition. Researchers will also check if food changes how the drug works. This study does not treat any disease but gathers key information for future trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGHubei, Wuhan, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scoliosis's hidden toll: can we predict lung and heart risks?
- Which breathing setting keeps Kids' lungs healthier during heart surgery?
- Could a simple sleep guide ease insomnia in lung disease?
- A Needle-Free heart check? MRI may replace invasive catheterization
- Can a diabetes drug help the lungs? pioglitazone put to the test for pulmonary hypertension
- Zapping lung nerves could ease heart Failure-Related high blood pressure